Evaluation of Bone Density Measurement in Type 2 Diabetic Postmenopausal Women with Hypertension and Hyperlipidemia

´ëÇÑÆó°æÇÐȸÁö 2015³â 21±Ç 1È£ p.36 ~ p.40

(Caglayan Emel Kiyak) - Bozok University Faculty of Medicine Department of Obstetrics and Gynecology
(Ungin-Ustun Yaprak) - Bozok University Faculty of Medicine Department of Obstetrics and Gynecology
(Sari Nagihan) - Bozok University Faculty of Medicine Department of Obstetrics and Gynecology
(Karacavus Seyhan) - Bozok University Faculty of Medicine Department of Nuclear Medicine
(Seckin Levent) - Bozok University Faculty of Medicine Department of Obstetrics and Gynecology
(Kara Mustafa) - Bozok University Faculty of Medicine Department of Obstetrics and Gynecology

Abstract

Objectives: The aim of the study was to compare bone mineral density (BMD) in healthy postmenopausal women to BMD in type 2 diabetic hypertensive postmenopausal women with hyperlipidemia.

Methods: Fifty type 2 diabetic and hypertensive postmenopausal women with hyperlipidemia and 51 age and body mass index (BMI) matched healthy postmenopausal women were included. Lumbar spine and femoral neck BMD were noted in both groups. BMD was measured using dual energy X-ray absorptiometry (DXA). Serum alkaline phosphatase (ALP), calcium and phosphorous were also measured. Pearson correlation coefficients were used to establish the relationship between various clinical characteristics.

Results: There were no significant differences between two groups in respect to lumbar and vertebral BMD values, age, BMI, gravidity, parity. Serum cholesterol and fasting glucose levels were significantly different between each groups (P = 0.0001, P = 0.002).

Conclusion: We found that, accompanying chronic diseases such as diabetes, hypertension and hyperlipidemia don¡¯t affect the BMD measurements at postmenopausal period. So these postmenopausal women don¡¯t have excess risk regarding osteoporosis.

Å°¿öµå

Bone density, Hyperlipidemias, Postmenopause
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
There are no significant differences between study group and control group in terms of BMD measurements.
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå